UK Markets open in 4 hrs 8 mins

Tiziana Life Sciences PLC (TLSA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.3800+0.0100 (+0.42%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.3700
Open2.3700
Bid2.3200 x 1000
Ask2.4300 x 1300
Day's range2.3000 - 2.4500
52-week range0.7843 - 12.1700
Volume103,106
Avg. volume1,048,093
Market cap212.114M
Beta (5Y monthly)-0.00
PE ratio (TTM)N/A
EPS (TTM)-0.1520
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.50
  • Globe Newswire

    Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

    NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with CEO and CSO Dr. Kunwar Shailubhai will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, May 8 at 7 p.m. local time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in approximately 73M homes. To view the interview segment, please visit: https://youtu.be/_S1mS9thG38 “The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. About Tiziana Life Sciences Tiziana Life Sciences plc (TLSA) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. For further enquiries: United Kingdom: Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder+44 (0)20 7495 2379 United States: Investors: Dave Gentry, CEORedChip Companies Inc.407-491-4498dave@redchip.com Source: Tiziana Life Sciences

  • Globe Newswire

    Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.

    Objective of this partnership with Takanawa Japan K.K., Pharma Team, is to identify a strategic partner in Japan for further development of Milciclib either alone or in combination with a tyrosine kinase inhibitor (TKI) for treatment of advanced HCC patients in Asian countries where prevalence of HCC is high, and the available therapeutic options are not entirely satisfactory. Milciclib, a broad-spectrum cyclin dependent kinase (pan-CDK) inhibitor, has successfully completed eight phase 1 and phase 2 trials in thymic carcinoma, thymoma and hepatocellular carcinoma (HCC), showing tolerability and positive clinical responses. Clinical data from Phase 2a trial, presented at the American Society of Clinical Oncology 2020, indicated that orally administered Milciclib in Sorafenib-resistant patients was well-tolerated, and it produced positive clinical responses. Tiziana was recently awarded a patent to use Milciclib in combination with a TKI or other drugs for treatment of HCC and other cancers. NEW YORK and LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces that it has executed an agreement with Takanawa Japan K.K, Pharma Team, (Takanawa) for a strategic business development plan to Identify a clinical partner in Japan and other Asian countries for further clinical development of Milciclib for treatment in advanced hepatocellular carcinoma (HCC) patients. HCC is the most common type of liver cancer and affects approximately 200,000 people per year. Previously, Tiziana successfully completed a Phase 2 clinical trial with orally administered Milciclib in sorafenib-resistant or intolerant HCC patients. The clinical data, presented at the American Society of Clinical Oncology (ASCO)1, demonstrated that the treatment was well-tolerated and produced clinical activity. Recently, a patent covering the use of Milciclib in combination with a tyrosine kinase inhibitor (TKI) or other drugs was granted2. The granted claims provide complete freedom to further develop a combination of Milciclib with an approved TKI for treatment of patients with advanced HCC or other cancers. Because the prevalence of HCC in Asian countries is large and there are no satisfactory therapeutic options for treatment of advanced HCC in Asian countries, the strategic initiative with Takanawa is particularly important to further develop Milciclib for the treatment of advanced HCC patients. “We are pleased and excited to work with Takanawa, a firm with a distinguished history of business development activities in the Japanese pharmaceutical industry, to identify an appropriate partner in Japan for further clinical development of Milciclib. We believe the positive clinical activity in advanced HCC and other cancers warrant immediate further development in Japan and other Asian countries where the prevalence of this cancer is relatively high, and the current available therapies are not entirely satisfactory” said Dr. Kunwar Shailubhai, CEO and CSO of Tiziana Life Sciences. “We are honored to get the opportunity to identify a strategic partner for Milciclib for the treatment of advanced hepatocellular carcinoma (HCC) patients. Tiziana has managed to develop a product that will really have an impact and save lives since HCC affects about 200,000 people in the world and 40,000 people in Japan every year. Therefore, we hope to receive a lot of interest from leading pharmaceutical companies ” said Dr. Kaoru Nozu, Executive Representative of the Takanawa Pharma Team.The person who arranged for the release of this announcement on behalf of the Company was Dr Kunwar Shailubhai, Chief Executive Officer and Chief Scientific Officer of the Company. Cited References: Abstract #298561: Phase 2a Safety and Efficacy of Milciclib, a Pan-Cyclin Dependent Kinase Inhibitor, in Unresectable, Sorafenib-Refractory or -Intolerant Hepatocellular Carcinoma Patients. First Author: Erica Villa, MD., et al.US Patent (10,758,541 B2 (Inventor: Shailubhai) Issue Date: September 1, 2020 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (THE "EUWA")) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. About MilciclibMilciclib (PHA-848125AC) is a small molecule inhibitor of several cyclin dependent kinases such as CDK1, CDK2, CDK4, CDK5 and CDK7. CDKs are serine threonine kinases that play crucial roles in progression of the cell cycle from G1 to S phase. Overexpression of CDKs and other downstream signalling pathways that regulate cell cycles have been frequently found to be associated with development of resistance towards chemotherapies. In a phase I study, oral treatment with Milciclib was found to be well-tolerated and the drug showed promising clinical responses in patients with advanced solid malignancies such as in NSCLC, pancreatic and colon cancer, thymic carcinoma and thymoma. About Tiziana Life SciencesTiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK LSE: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation, and infectious diseases. In addition to Milciclib, the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn’s Disease and nasally administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (“mAb”) in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (“T1D”), inflammatory bowel disease (“IBD”), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin 6 receptor (“IL6R”) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients. About Takanawa Takanawa is a global consulting, development and trading company, with a very strong Pharma Team. In that area Takanawa develops its own pharma projects, advises cross border pharma transactions, licensing, and alliances. Takanawa also supports companies entering the Japanese and Asian market as well as Japanese companies to enter overseas markets. Takanawa’s seasoned pharma specialists are both high level scientists with research background from USA (Bethesda), NCI and NIH, and from Japan, the Japanese Foundation for Cancer Research, Japan National Institute of Radiological Medicines, Tokyo University and Kyoto University, as well as experienced business people from leading pharma companies like Sanofi, Kyowa Kirin, Yakult and Actavis, with an extensive track record and network. Examples of known oncology products Takanawa specialists have been involved with in their previous positions are oxaliplatin, camptothecin (irinotecan), G-CSF, docetaxel, epirubicin, gemcitabine, vinorelbine and 5-FU. For further information please see www.takanawa.is/pharmaceuticals. Forward-Looking StatementsCertain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. For further enquiries: United Kingdom: Tiziana Life Sciences plc+44 (0)20 7495 2379Gabriele Cerrone,Chairman and founderUnited States:Investors:Dave Gentry, CEORedChip Companies Inc.407-491-4498dave@redchip.com

  • Stocks That Soared on Covid Treatments Are Coming Back to Earth
    Bloomberg

    Stocks That Soared on Covid Treatments Are Coming Back to Earth

    (Bloomberg) -- Covid-19 case numbers are soaring and health authorities are getting increasingly worried about coronavirus variants, yet investors are growing less optimistic about many of the companies that are trying to develop treatments for the infection.Many of the stocks that skyrocketed in 2020 -- including Tiziana Life Sciences Plc and Sorrento Therapeutics Inc. -- have fallen from their highs amid mounting expectations that the pandemic can be suppressed through vaccination. At the same time, some biotechs such as France’s Abivax SA have abandoned trials for drugs to fight infection with the coronavirus.“If share prices of these companies implicitly assume that many, many people will be treated every year then they’re clearly overvalued,” said Adam Barker, an analyst at Shore Capital.To be sure, the surge in coronavirus cases in countries such as India shows that treatments will still be needed as new strains of the disease emerge that can escape first-generation immunity. It’s just turning out to be harder to develop effective drugs than the most optimistic investors expected.There are hundreds of drugs in development for Covid-19. Ten have been approved for emergency use by the U.S. Food & Drug Administration and only one, Gilead Sciences Inc.’s remdesivir antiviral, has won full approval.That drug hasn’t been shown to reduce deaths from the virus, only to reduce the time needed to recover from it. A surge in sales of the product hasn’t helped the stock price: Gilead is up about 8% since winning regulatory backing, underperforming an index of health-care stocks in the U.S.Here’s a roundup of some of the Covid treatment stocks and where they stand more than a year on from the onset of the pandemic.Tiziana Life Sciences Plc: -68% from 2020 peakTiziana peaked in July when it sought a U.S. patent for its monoclonal antibody TZLS-501 in the treatment of Covid-19. The company launched its first clinical trial for the nasally administered treatment in November, with positive results reported at the start of February. It’s planning to begin larger trials on both outpatients and inpatients, said Howard Weiner, a scientific advisor for Tiziana. The shares have fallen 7.1% this year. Humanigen Inc.: -47% from 2020 peakHumanigen shares soared 618% last year. Preliminary data last month from a late-stage trial showed that its lenzilumab drug increased survival of hospitalized patients without the need for ventilation. The company has shared the results with regulators worldwide and plans to apply for approval, Chief Executive Officer Cameron Durrant said by email. Analysts are still bullish: Six of the seven tracked by Bloomberg have buy or equivalent ratings on the stock.Vir Biotechnology Inc.: -42% from Jan. 2021 peakVir more than doubled last year and then surged anew early in 2021, causing losses for short sellers who had bet on the stock declining. Late-stage trial data subsequently showed the U.S. company’s VIR-7831 antibody, developed with GlaxoSmithKline Plc, led to a significant reduction of hospitalization and death. The companies applied for emergency-use clearance in the U.S. on March 26 and the drug is being reviewed by the European Union. The stock has pulled back to below $49 as a Reddit-fueled frenzy in the most-shorted names cooled down. Analysts are mostly bullish on Vir, though their price targets range from $33 to $135, reflecting a wide range of possible outcomes. JPMorgan Chase & Co., the lone bear on the stock, says, “Valuation is a concern.”Synairgen Plc: -40% from 2020 peakSynairgen’s 2,520% gain last year was the biggest in the FTSE AIM All Share Index. In a clinical trial, SNG001, the company’s formulation of the human protein interferon beta, cut the risk of patients developing the worst symptoms of Covid-19. Now Synairgen has begun dosing in a late-stage trial of hospitalized patients and begun a mid-stage study in people not requiring hospitalization.“Synairgen has shown early proof-of-concept data that suggest their medicine could provide a profound benefit to patients, potentially materially better than anything we have seen to date from some of the higher-profile companies,” said David Pinniger, lead manager of the Polar Capital Biotechnology Fund, who owns the stock.Sorrento Therapeutics Inc.: -55% from 2020 peakThe shares surged in May 2020 and again in August after the San Diego-based company said it discovered an antibody that could protect against Covid-19, only to have skeptical short sellers pile in to bet against it. It still ended 2020 up more than 100%. Early-stage data from a handful of Covid-19 patients sent the shares higher again in January, though they have since dropped off. The company said last week it plans a bigger study. Sorrento is studying experimental treatments for other illnesses as well that may pay off, said Raghuram Selvaraju, an analyst at H.C. Wainwright & Co. “Sorrento’s antibody pipeline is broad and diverse, while also rapidly advancing in maturity,” he wrote in a report this week, reiterating his buy recommendation.Celltrion Inc.: -32% from 2020 peakCelltrion shares more than doubled last year. The company received conditional approval from South Korea in February for its antibody treatment, regdanvimab, in high-risk patients with mild to moderate Covid-19 symptoms. The EU regulator in March said the product can be used in some high-risk adult patients, though data from an ongoing study wasn’t robust enough to reach a firm conclusion on the medicine’s benefits. Celltrion is working on its Phase 3 clinical trial on about 1,300 people and plans to get results by the end of June, a spokesman said.Abivax SA: -37% from Jan. 2021 peakThe French drugmaker’s stock jumped 53% last year. In March the company ended trials of its anti-inflammatory drug ABX464 in Covid-19 patients after it showed no signs of efficacy. The shares fell the most in almost five years, despite analysts stressing the drug’s potential in other uses such as for ulcerative colitis and inflammatory bowel disease. The six analysts tracked by Bloomberg who cover Abivax see about 65% upside, on average, for the stock.BerGenBio ASA: -37% from 2020 peakThe Norwegian company’s stock almost doubled through mid-May last year, only to give up half the gains after the U.K. pulled funding in July for a study in which its bemcentinib was the lead drug candidate to be tested. Short interest has climbed as investors await data from a mid-stage trial in hospitalized Covid-19 patients. Preliminary data released this month showed the drug was well-tolerated with no safety issues, while more detailed data is expected in May.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.